Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis - PubMed (original) (raw)

Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis

G A Tennent et al. Proc Natl Acad Sci U S A. 1995.

Abstract

Extracellular deposition of amyloid fibrils is responsible for the pathology in the systemic amyloidoses and probably also in Alzheimer disease [Haass, C. & Selkoe, D. J. (1993) Cell 75, 1039-1042] and type II diabetes mellitus [Lorenzo, A., Razzaboni, B., Weir, G. C. & Yankner, B. A. (1994) Nature (London) 368, 756-760]. The fibrils themselves are relatively resistant to proteolysis in vitro but amyloid deposits do regress in vivo, usually with clinical benefit, if new amyloid fibril formation can be halted. Serum amyloid P component (SAP) binds to all types of amyloid fibrils and is a universal constituent of amyloid deposits, including the plaques, amorphous amyloid beta protein deposits and neurofibrillary tangles of Alzheimer disease [Coria, F., Castano, E., Prelli, F., Larrondo-Lillo, M., van Duinen, S., Shelanski, M. L. & Frangione, B. (1988) Lab. Invest. 58, 454-458; Duong, T., Pommier, E. C. & Scheibel, A. B. (1989) Acta Neuropathol. 78, 429-437]. Here we show that SAP prevents proteolysis of the amyloid fibrils of Alzheimer disease, of systemic amyloid A amyloidosis and of systemic monoclonal light chain amyloidosis and may thereby contribute to their persistence in vivo. SAP is not an enzyme inhibitor and is protective only when bound to the fibrils. Interference with binding of SAP to amyloid fibrils in vivo is thus an attractive therapeutic objective, achievement of which should promote regression of the deposits.

PubMed Disclaimer

Cited by

Inflammatory Biomarkers Predict Domain-Specific Cognitive Decline in Older Adults.
Chi GC, Fitzpatrick AL, Sharma M, Jenny NS, Lopez OL, DeKosky ST. Chi GC, et al. J Gerontol A Biol Sci Med Sci. 2017 Jun 1;72(6):796-803. doi: 10.1093/gerona/glw155. J Gerontol A Biol Sci Med Sci. 2017. PMID: 27522059 Free PMC article. Clinical Trial.
Antibodies to human serum amyloid P component eliminate visceral amyloid deposits.
Bodin K, Ellmerich S, Kahan MC, Tennent GA, Loesch A, Gilbertson JA, Hutchinson WL, Mangione PP, Gallimore JR, Millar DJ, Minogue S, Dhillon AP, Taylor GW, Bradwell AR, Petrie A, Gillmore JD, Bellotti V, Botto M, Hawkins PN, Pepys MB. Bodin K, et al. Nature. 2010 Nov 4;468(7320):93-7. doi: 10.1038/nature09494. Epub 2010 Oct 20. Nature. 2010. PMID: 20962779 Free PMC article.
Selective protein aggregation confines and inhibits endotoxins in wounds: Linking host defense to amyloid formation.
Petrlova J, Hartman E, Petruk G, Lim JCH, Adav SS, Kjellström S, Puthia M, Schmidtchen A. Petrlova J, et al. iScience. 2023 Sep 19;26(10):107951. doi: 10.1016/j.isci.2023.107951. eCollection 2023 Oct 20. iScience. 2023. PMID: 37817942 Free PMC article.
Common Factors of Alzheimer's Disease and Rheumatoid Arthritis-Pathomechanism and Treatment.
Trzeciak P, Herbet M, Dudka J. Trzeciak P, et al. Molecules. 2021 Oct 5;26(19):6038. doi: 10.3390/molecules26196038. Molecules. 2021. PMID: 34641582 Free PMC article. Review.
Apolipoproteins and amyloid fibril formation in atherosclerosis.
Teoh CL, Griffin MD, Howlett GJ. Teoh CL, et al. Protein Cell. 2011 Feb;2(2):116-27. doi: 10.1007/s13238-011-1013-6. Epub 2011 Mar 12. Protein Cell. 2011. PMID: 21400045 Free PMC article. Review.

References

1. Neuropathol Appl Neurobiol. 1988 Mar-Apr;14(2):169-74 - PubMed
1. Brain Res. 1991 May 10;548(1-2):349-52 - PubMed
1. Q J Med. 1988 Apr;67(252):283-98 - PubMed
1. Virchows Arch B Cell Pathol Incl Mol Pathol. 1989;56(4):259-62 - PubMed
1. Acta Neuropathol. 1989;78(4):429-37 - PubMed

Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis - PubMed (original) (raw)